 Hello Immunization Partners,
Please share the following information with staff and colleagues.
On August 6, 2024, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (MMWR) titled Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. This report summarizes the Advisory Committee on Immunization Practices (ACIP) recommendations for Respiratory Syncytial Virus (RSV) vaccine for adults aged 60 years and older voted on in June.
On June 26, 2024, ACIP recommended a single dose of any FDA-approved RSV vaccine for all adults aged 75 years and older and for adults aged 60 through 74 years who are at increased risk for severe RSV disease.
Adults who have previously received RSV vaccine should not receive another dose. Adults aged 60 through 74 years who are at increased risk include persons with certain chronic medical conditions, persons with moderate or severe immune compromise, and persons living in nursing homes. More information on risk factors associated with severe RSV disease can be found at this link https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#risk-factors.
Qualified vaccinators, including pharmacists, nurse practitioners, and other providers (based on state and jurisdictional law) may determine patient eligibility for RSV vaccination based on clinical assessment even in the absence of medical documentation of a named risk condition. Patient attestation is sufficient evidence of the presence of a risk factor; vaccinators should not deny RSV vaccination to a person because of lack of documentation. These factors should be considered to optimize patient access, including in administrative procedures, such as reimbursement policies for RSV vaccination.
These recommendations replace the June 2023 shared clinical decision-making recommendation for RSV vaccination for adults aged 60 years and older and apply to all RSV vaccines licensed for adults aged 60 years and older (i.e., Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]).
As a reminder, eligible adults are currently recommended to receive a single dose of RSV vaccine; adults who have already received RSV vaccination should not receive another dose. A single dose provides protection for at least two RSV seasons. The need for additional RSV vaccine doses will be evaluated by ACIP in the future; ACIP will update recommendations as needed.
As for timing of administration, eligible adults who have not previously received RSV vaccination may be vaccinated at any time of year, but vaccination will have the most benefit if administered in late summer or early fall, just before the RSV season. In most of the continental United States, this corresponds to vaccination during August–October.
Thank you for all you do!
Oakland County Health Division, Immunization Action Plan
|
